Lantern Pharma (LTRN) Q1 2025 earnings summary

Executive summary

• Achieved pivotal milestones in clinical-stage oncology portfolio, including nearing full enrollment in LP-184 Phase 1a and advancing the LP-300 HARMONIC™ trial with expansion into Asia, while expanding the RADRⓇ AI platform to over 200 billion oncology-focused data points and new modules for ADC and BBB prediction.

• Progressed three strategic pillars: clinical pipeline, AI platform commercialization, and shareholder value maximization, with objectives including monetizing Starlight Therapeutics and expanding RADRⓇ platform commercialization.

• Maintained strong capital discipline, ending Q1 2025 with $19.7 million in cash, cash equivalents, and marketable securities, providing an operating runway through at least mid-May 2026.

• Focused on AI-driven oncology drug development, with three clinical-stage candidates (LP-300, LP-184, LP-284), an ADC program, and ongoing preclinical research leveraging the RADRⓇ platform.

Financial highlights

• Ended Q1 2025 with $19.7 million in cash, cash equivalents, and marketable securities, down from $24.0 million at year-end 2024.

• Net loss for Q1 2025 was $4.54 million ($0.42/share), improved from $5.44 million ($0.51/share) year-over-year, driven by lower R&D expenses.

• R&D expenses declined to $3.26 million from $4.3 million year-over-year; G&A expenses were $1.51 million, up slightly from $1.48 million.

• Operating expenses decreased to $4.77 million from $5.73 million year-over-year.

• No revenue was recognized; operations are funded primarily by equity sales.

Outlook and guidance

• LP-184 Phase 1a trial enrollment expected to complete by end of June 2025, with comprehensive data readouts to follow and broader data update in Q3 2025.

• Harmonic trial (LP-300) expansion cohort results, including Asian patients, anticipated in Q3 2025.

• Planned initiation of FDA-cleared Phase 1b/2 trials for LP-184 in TNBC and biomarker-defined NSCLC, and an investigator-led bladder cancer trial in Denmark in Q3 2025.

• Commercial launch of select RADRⓇ AI modules, including BBB permeability prediction, expected in the second half of 2025.

• Existing cash and equivalents expected to fund operations for at least 12 months from the filing date, with additional funding required for future development.